Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05022901 · ClinicalTrials.gov registry record · Phase 3
An Open-Label Expanded Access Study of the Melphalan/Hepatic Delivery System (HDS) in Patients With Hepatic Dominant Ocular Melanoma
A Phase 3 study, sponsored by Delcath Systems.
- Active
- Registry status
- Phase 3
- Development phase
- 30
- Enrollment target
NCT05022901: Active Phase 3 study, sponsored by Delcath Systems.
NCT05022901 is a Phase 3 study that is active but no longer recruiting, run by Delcath Systems. The registered enrollment target is 30 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (96% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05022901, a Phase 3 study, is active but no longer recruiting, sponsored by Delcath Systems.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 3
- Development phase
- 30 participants
- Enrollment target
Study Summary
Patients in the study will be treated with Melphalan/HDS and will receive up to 6 total treatments. This study will evaluate the safety and effects of the treatment.
Primary Outcome
The number and type of adverse events will be assessed per CTCAE version 5.0.
Interventions
- COMBINATION_PRODUCT Melphalan (3 mg/kg IBW) with Hepatic Delivery System (HDS)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2022-06-10 |
| Est. Completion | 2024-03-01 |
| Phase | Phase 3 |
What the registry record for NCT05022901 still lists
NCT05022901 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 30 participants, a relatively small participant target, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (96% lower).
The record links to 0 conditions, and to 1 intervention - of which Melphalan (3 mg/kg IBW) with Hepatic Delivery System (HDS) is the first listed.
NCT05022901 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05022901 about?
NCT05022901 is a clinical study titled "An Open-Label Expanded Access Study of the Melphalan/Hepatic Delivery System (HDS) in Patients With Hepatic Dominant Ocular Melanoma". Patients in the study will be treated with Melphalan/HDS and will receive up to 6 total treatments. This study will evaluate the safety and effects of the treatment.
What is the current status of trial NCT05022901?
This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 30 participants. The study started on 2022-06-10. Estimated completion is 2024-03-01.
What interventions are being tested in trial NCT05022901?
The interventions under investigation include: Melphalan (3 mg/kg IBW) with Hepatic Delivery System (HDS) (COMBINATION_PRODUCT).
Who is sponsoring clinical trial NCT05022901?
This trial is sponsored by Delcath Systems, which has 6 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT05022901's enrollment target sits among peer trials
30 1917th of 2000 higher than 68 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00977977 · 30 participants · Phase 2
Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy
- NCT01459107 · 30 participants · Phase 2
Human Upper Extremity Allotransplantation
- NCT01666080 · 30 participants · NA
Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)
- NCT01720836 · 30 participants · Phase 1
Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI